CPC213

CPC213 is a preclinical-stage small molecule drug candidate developed by Alephoson Biotherapeutics for the treatment of non-infectious uveitis (NIU), encompassing both anterior and posterior manifestations. The asset leverages Alephoson's proprietary Cell-Penetrating Complex (CPC) technology, a delivery platform intended to enhance the penetration of therapeutic molecules through ocular barriers such as the corneal epithelium. By improving the bioavailability of the small molecule within the eye, CPC213 aims to provide a potent anti-inflammatory effect for ocular diseases that are typically difficult to treat with conventional topical administrations.